{"id":"NCT01212471","sponsor":"Bausch & Lomb Incorporated","briefTitle":"A Dose Ranging Study to Evaluate Safety and Efficacy of Bromfenac Ophthalmic Solution in Dry Eye Disease","officialTitle":null,"status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-09","primaryCompletion":"2011-08","completion":"2011-12","firstPosted":"2010-09-30","resultsPosted":"2020-09-04","lastUpdate":"2020-09-04"},"enrollment":840,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Dry Eye Syndrome"],"interventions":[{"type":"DRUG","name":"Bromfenac Ophthalmic Solution A","otherNames":[]},{"type":"DRUG","name":"Bromfenac Ophthalmic Solution B","otherNames":[]},{"type":"DRUG","name":"Placebo Comparator","otherNames":[]}],"arms":[{"label":"Bromfenac Ophthalmic Solution A","type":"EXPERIMENTAL"},{"label":"Bromfenac Ophthalmic Solution B","type":"EXPERIMENTAL"},{"label":"Placebo Comparator","type":"PLACEBO_COMPARATOR"}],"summary":"A dose ranging study to evaluate safety and efficacy of bromfenac ophthalmic solution in dry eye disease.","primaryOutcome":{"measure":"Mean Ocular Surface Disease Index (OSDI) Total Score","timeFrame":"42 days","effectByArm":[{"arm":"Bromfenac Ophthalmic Solution 0.06%","deltaMin":35,"sd":22.23},{"arm":"Bromfenac Ophthalmic Solution 0.03%","deltaMin":40.3,"sd":25.22},{"arm":"Placebo Comparator","deltaMin":36.9,"sd":23.24}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":1},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":141},"commonTop":["Dry eye"]}}